Economy/Home · Economy

SK Biopharmaceuticals Rises 0.27% in Morning Session... Xcopri Approval in Japan Expected to Lift Q3 Operating Profit to 102 Billion Won

SK Biopharmaceuticals (326030) was trading 200 won (0.27%) higher than the previous day in the morning session on the 21st. DS Investment & Securities projected that SK Biopharmaceuticals' third-quarter revenue and operating profit this year will increase compared to the same period last year. This

Wooil Shim
Staff Reporter
4 min read
SK Biopharmaceuticals Rises 0.27% in Morning Session... Xcopri Approval in Japan Expected to Lift Q3 Operating Profit to 102 Billion Won
CBC News

SK Biopharmaceuticals (326030) was trading 200 won (0.27%) higher than the previous day in the morning session on the 21st.

DS Investment & Securities projected that SK Biopharmaceuticals' third-quarter revenue and operating profit this year will increase compared to the same period last year. This outlook reflects the milestone payment following Xcopri's approval in Japan.

Q3 Revenue and Operating Profit Both Expected to Rise

DS Investment & Securities estimated SK Biopharmaceuticals' third-quarter 2026 revenue at approximately 247.7 billion won, up 29.2% year-on-year. Over the same period, operating profit was projected to rise about 45.6% to roughly 102 billion won, with an expected operating margin of around 41.2%. The securities firm forecast that the year-on-year growth rate of operating profit would be higher than that of revenue.

Xcopri's Japan Approval Milestone Offsets Unfavorable Currency Effects

The key factor in this earnings outlook is Xcopri's entry into the Japanese market. According to DS Investment & Securities, Xcopri received approval in Japan on September 16. The firm analyzed that the resulting milestone payment offset the unfavorable currency effects, explaining that while exchange rates worked against earnings, the milestone tied to the Japanese approval compensated for this.

DS Investment & Securities framed the theme of its third-quarter outlook as 'a gateway to becoming a company capable of sustained growth,' highlighting the expected simultaneous increase in revenue and operating profit as well as the impact of the Japanese approval on results.

[This article is provided for informational purposes as an investment reference and does not recommend buying or selling any specific stock. Conditions may vary depending on market circumstances. Investment decisions and any resulting responsibility rest with the investor. AI provided some assistance.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.